Carmell Corporation

NCT00083694

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

NCT00083707

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

NCT00193102

Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer

NCT00046514

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

NCT00446433

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

NCT00051116

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

NCT00040391

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

NCT00047476

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

NCT00540917

Measurement Skin Temperature During Pulsed Laser Exposure

NCT00098865

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

NCT00226980

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

NCT00064974

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

NCT00209014

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

NCT00067743

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

NCT00072722

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00162760

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

NCT00412542

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

NCT00091260

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

NCT00087672

A Phase II Study of CC-5013 in Myelofibrosis

NCT00142168

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

NCT00151203

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

NCT00106431

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

NCT00109772

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

NCT00140452

Phase II Study Using Thalidomide for the Treatment of ALS

NCT00179686

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

NCT00251472

A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

NCT00179738

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

NCT00110695

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

NCT00569660

Ph II Study of Azacitidine in Myelofibrosis

NCT00128583

Vaccine Therapy in Treating Patients With Malignant Melanoma

NCT00284505

Use of Thalidomide in Patients With Arachnoiditis

NCT00326170

Phase II 5-Azacytidine Plus VPA Plus ATRA

NCT00981903

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00179660

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00284752

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

NCT00469703

Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis

NCT00165477

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00193206

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

NCT00319865

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

NCT00466986

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

NCT00267059

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

NCT00287287

REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

NCT00301405

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

NCT00319969

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

NCT00384839

Vidaza to Restore Hormone Thx Prostate

NCT00454324

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

NCT00953615

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

NCT00322985

A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

NCT00349115

TCD Followed by autoSCT for Newly Diagnosed MM Patients

NCT00352794

Lenalidomide for Patients With Myelofibrosis (MF)

NCT00446303

A Phase II Study of Maintenance With Azacitidine in MDS Patients

NCT00378209

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT00387647

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

NCT00379353

The Effects of Thalidomide on Symptom Clusters

NCT00379912

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

NCT00413478

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

NCT00392392

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

NCT00478959

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

NCT00407563

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

NCT00462423

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

NCT00474188

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00479674

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

NCT00483301

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

NCT00482261

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

NCT00521781

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

NCT00540007

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

NCT00607438

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT00625573

Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)

NCT00609869

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

NCT00654836

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00585689

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

NCT00518284

Prevention of Restenosis Following Revascularization

NCT00617591

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

NCT00607581

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

NCT00628238

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

NCT00632359

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

NCT00654186

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

NCT00860457

Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

NCT01222195

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

NCT00683059

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

NCT00903942

Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)

NCT00629499

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

NCT00642759

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

NCT00665652

Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

NCT00675441

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

NCT00720850

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

NCT00684242

Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

NCT00701311

An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT00957385

Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

NCT00675259

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

NCT00721214

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

NCT00729612

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00691704

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

NCT00738361

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

NCT00759603

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

NCT00869089

Safety and Efficacy of CC-10004 for Prurigo Nodularis

NCT00777673

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

NCT00736944

Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer

NCT00813124

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

NCT00814632

CC-10004 For The Treatment Of Vulvodynia

NCT00360672

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

NCT00495547

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

NCT00837031

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

NCT00847639

Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma

NCT00885508

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

NCT01015352

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

NCT01553357

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

NCT00899431

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

NCT01393158

Apremilast for Atopic Dermatitis - A Pilot Study in Adults

NCT01178814

Revlimid in Transfusion Dependent Patients

NCT00925821

Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

NCT00931242

Study of Apremilast in Atopic or Contact Dermatitis

NCT00915252

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT00944047

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

NCT00944658

Spondylitis Trial of Apremilast for Better Rheumatic Therapy

NCT01206205

Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

NCT00948064

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT00965718

Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer

NCT01160484

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

NCT00974233

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

NCT00995488

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

NCT01053949

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

NCT01011894

Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age

NCT01032291

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

NCT01116193

Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia

NCT01041625

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

NCT01133665

Cetuximab and Lenalidomide in Head and Neck

NCT01133275

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

NCT00997581

Apremilast Therapy for Acute Gouty Arthritis

NCT01083706

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

NCT01135199

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT01123356

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

NCT01127542

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

NCT01132989

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

NCT01133743

Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia

NCT01045551

Open Label Pilot Study of Apremilast in Treatment of Rosacea

NCT01241786

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

NCT01155362

A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01199575

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT01200472

Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis

NCT01380106

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

NCT01088815

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

NCT01204138

Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA

NCT01036087

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

NCT01261403

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

NCT01274533

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

NCT01488565

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia

NCT01301820

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

NCT01379274

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

NCT01401322

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT01310114

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

NCT01353664

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

NCT01298011

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

NCT01319422

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

NCT01207102

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

NCT01442714

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

NCT01282047

Lenalidomide in Kaposi Disease Associated With HIV Infection

NCT01373294

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01600053

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

NCT01446133

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

NCT01518465

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

NCT01497496

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT01349569

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

NCT01745640

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

NCT01723839

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

NCT01412229

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT01496976

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

NCT01465230

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

NCT01652781

5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

NCT01701076

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

NCT01779167

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

NCT01643330

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT01639898

POEMS Syndrome Treatment With Lenalidomide

NCT01675141

Lenalidomide Maintenance Therapy for Multiple Myeloma

NCT01620190

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

NCT01745588

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01790737

First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02

NCT01794169

Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML

NCT02060656

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

NCT01702831

Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

NCT01754857

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

NCT01754870

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

NCT01964534

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

NCT01897610

Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC

NCT02011113

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

NCT01966887

AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure

NCT02017457

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

NCT01933061

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

NCT02052388

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02073487

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

NCT01816620

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

NCT02076243

Treatment With Nab-paclitaxel in Cutaneous SCC

NCT02244125

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial

NCT02106884

Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel

NCT02176213

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT02188368

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

NCT00534703

Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure

NCT01924169

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT02125136

Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

NCT02181634

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma

NCT02270814

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

NCT02259582

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

NCT02405910

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

NCT02289898

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT02415413

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

NCT02472691

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT

NCT02486601

NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma

NCT02494479

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

NCT02525653

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

NCT02633137

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

NCT02427841

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02573493

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

NCT02716038

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

NCT02769832

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

NCT02854839

A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

NCT02723331

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

NCT02564146

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

NCT02967133

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

NCT02371577

Evaluation of the Immune Restoration Potential Of Lenalidomide

NCT02682693

Denosumab as an add-on Neoadjuvant Treatment (GeparX)

NCT03160248

An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema

NCT03283761

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

NCT03270059

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

NCT03239106

A Study Examining the Medication Apremilast as Treatment for Chronic Itch

NCT03784287

A Treatment Extension Study of Mucopolysaccharidosis Type IIIB

NCT02371590

Lenalidomide and Obinutuzumab for Previously Untreated CLL

NCT03289819

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

NCT02856815

"Safety and Efficacy of Immuncell-LC in TACE Therapy"

NCT03542266

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma